![Jacob Adashek: Comparing and contrasting Figures 1 from NRG1 papers from 2020 Clinical Cancer Research of AACR and 2024 BMC Medicine from our paper](https://oncodaily.com/pub/uploads/2024/04/Jacob-Adashek.jpg)
Jacob Adashek: Comparing and contrasting Figures 1 from NRG1 papers from 2020 Clinical Cancer Research of AACR and 2024 BMC Medicine from our paper
Jacob Adashek, Medical Oncology Fellow at the Sidney Kimmel Comprehensive Cancer Center, shared on X/Twitter:
“Who did it better?! Comparing and contrasting Figures 1 from NRG1 papers from 2020 Clinical Cancer Research of AACR and 2024 BMC Medicine from our paper!
Honestly, I love the tactfulness and clarity!
Oncogenic NRG1 fusions: A new hope for targeted therapy in pancreatic cancer vs Neuregulin-1 and ALS19 (ERBB4): at the crossroads of amyotrophic lateral sclerosis and cancer
Razelle Kurzrock, what do you think?”
Source: Jacob Adashek/X
About OncoDaily
OncoDaily was founded in 2023. It is a US-based oncology media platform, which features the latest news, insights, and patient stories from the world of oncology. Within a short period of time it became one of the leading oncology media platforms globally.
OncoDaily gathers content from various sources, including social media posts from renowned oncologists from all over the world, news from oncology societies and cancer centers, patient and survivor stories, and career-related information for professionals.
The mission of OncoDaily is to empower patients, survivors, and professionals with the knowledge and inspiration they need to fight cancer. The motto of OncoDaily is “Cancer doesn’t take a day off – neither do we”.